Search for dissertations about: "Urinary bladder carcinoma"
Showing result 1 - 5 of 27 swedish dissertations containing the words Urinary bladder carcinoma.
-
1. Quantitative immunochemistry in tissue sections : With special reference to urinary bladder carcinoma
Abstract : Urinary bladder carcinoma affects about 2 000 people in Sweden every year. It is a heterogeneous disease and for adequate treatment decisions, prognostic tools are needed. Many of these are based on immunohistochemistry (MC) and hampered by poorly reproducible methodologies and subjective evaluations. READ MORE
-
2. Stage T1 Urinary Bladder Carcinoma : Investigation of A Population-Based Cohort
Abstract : Approximately 2 300 new cases of urinary bladder carcinoma (UBC) are diagnosed every year in Sweden. This type of cancer is characterized as a long-standing disease with a high risk of recurrence and progression from an indolent to a more aggressive course. READ MORE
-
3. Cancer Immunotherapy : A Preclinical Study of Urinary Bladder Cancer
Abstract : Bacillus Calmette Guérin (BCG), or attenuated Mycobacterium bovis, is the gold standard of immunotherapy in the clinic to treat superficial bladder cancer. However, setbacks remain due to a high recurrence rate, side effects, and BCG-refractory disease. READ MORE
-
4. Urinary bladder carcinoma, preclinical and clinical studies on EGFR based targeting
Abstract : Radical cystectomy with bilateral pelvic lymphadenectomy is the standard treatment for muscle-invasive transitional cell carcinoma of the urinary bladder. Despite presumably localised malignancies and efficacious management about 50% of patients will die within 5 years, the majority due to metastatic disease. READ MORE
-
5. Urinary Bladder Carcinoma – Studies of Outcome of Current Management and Experimental Therapy
Abstract : The thesis concerns the epidemiology, current and possible future treatment of urothelial cancer of the urinary bladder. The Swedish National Quality Registry for Bladder Cancer 1997-2001 was used to explore epidemiology, current therapies and outcome. More common in men, the incidence for Ta and T1 tumours peaks in the age range 70-79 years. READ MORE